Across TCGA pan-cancer cohorts, DNM1P30 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated DNM1P30 data layer compared with 7 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher DNM1P30 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DNM1P30 expression acts as an unfavorable survival marker.
UCEC are the cancer types where DNM1P30 Mutation most reproducibly stratifies survival.